Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
August 4, 2015 7:00 AM EDT
Company to evaluate strategic alternatives for Sagent (China) Pharmaceuticals
Company modifies earnings guidance for 2015
SCHAUMBURG, Ill., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Highlights
Revenue increased 12% to $77.3 million driven primarily by the October 1, 2014 acquisition of Omega Laboratories Limited ("Omega");
Reported gross profit declined 18% to $18.4 million, or 23.8% of net revenue;...
More
August 3, 2015 4:25 PM EDT
SCHAUMBURG, Ill., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectables market, today announced that its Board of Directors has named Allan Oberman as Chief Executive Officer and a member of the Board of Directors, effective immediately upon receipt of a US work visa.
"Allan is a proven leader with impeccable credentials and strategic instincts that will serve Sagent well as we enter our next phase of growth," said Robert J. Flanagan, Chairman of Sagent's Board of Directors. "Allan... More
